News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Ipsen: Total Number of Outstanding Shares and Voting Rights, Pursuant to Article 223-16 Of the General Regulation of the Autorité Des Marchés Financiers
December 9, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS--(BUSINESS WIRE)--Regulatory News: IPSEN (Paris:IPN)
Twitter
LinkedIn
Facebook
Email
Print
Europe
Ipsen Biopharmaceuticals, Inc.
MORE ON THIS TOPIC
Insights
Golden Triangle still dominates, but talent and capital gaps slow biotech growth
July 1, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Insights
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
June 12, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Insights
Portugal, Spain and the new biotech frontier
June 11, 2026
·
1 min read
·
Jennifer C. Smith-Parker
